SERINA THERAPEUTICS INC.
SERNYSE AMERICANTrading Snapshot
- Day Range
- $1.06 β $1.23
- 52-Week Range
- $1.06 β $4.26
- Volume (shares)
- 62,151
- Avg Volume (shares)
- β
- Shares Outstanding
- 25.4M
- Next Earnings
- 2027-03-30
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- $125,000
- P/E Ratio
- β
- P/S Ratio
- 206.7x
- EPS (TTM)
- $-1.14
- Dividend Yield
- β
- Dilution (1yr)
- β5.2%
SERINA THERAPEUTICS INC.
SERAbout SERINA THERAPEUTICS INC.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
β Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2Β β Dosing initiated in Cohort 2 of the registrational study ; topline single-ascending-dose data expected in

Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155 Seres expects to su

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data from the study support

Custom Truck One Source, Inc. Reports Record Third Quarter 2026 Results and Increases Full Year 2026 Adjusted EBITDA and SER Revenue Guidance
KANSAS CITY, Mo.--(BUSINESS WIRE)--Custom Truck One Source, Inc. (NYSE: CTOS), a leading provider of specialty equipment to the electric utility, telecom, rail, forestry, waste management and other infrastructure-related

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Novel oral liquid formulationΒ of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar EventΒ "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"
Featuring Serina Therapeutics' CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson's disease with no major clinical advances in 50+ years Meet with Serina's CEO Steven Ledger Regist